SITC Archive Library

2014 Hot Topic Symposium I: Accelerating Tumor Immunity with Agonist Antibodies 

02-21-2017 15:32

2014 Hot Topic Symposium I: Accelerating Tumor Immunity with Agonist Antibodies
November 6, 2014
Gaylord National Hotel & Convention Center National Harbor, MD

Program Organizers
Michael A. Curran, PhD –University of Texas, MD Anderson Cancer Center
Ronald Levy, MD – Stanford University
Andrew D. Weinberg, PhD – Earle A. Chiles Research Institute, Providence Portland Medical Center

Program Summary
From the Society for Immunotherapy of Cancer (SITC), these enduring materials from the 2014 Hot Topic Symposium I: Accelerating Tumor Immunity with Agonist Antibodies address how activation of stimulatory receptors on both T cells and antigen presenting cells can enhance tumor immunity both in animal models and in clinical trials. Tumors locally attenuate T cells through engagement of co-inhibitory receptors, as well as by depriving their microenvironment of the positive co-stimulation signals necessary for these cells to robustly expand and acquire high-levels of effector function. Antibodies which block immune checkpoint receptors have proven capable of extending survival and inducing tumor regression in patients suffering from a variety of metastatic cancers leading to FDA approval for Ipilimumab (a-CTLA-4) in 2011 and likely approval of multiple PD-1 blocking antibodies in the coming months. In contrast, antibodies designed to activate co-stimulatory receptors on T cells and/or antigen-presenting cells to promote enhanced survival, proliferation, and effector function have yet to move beyond early phase clinical trials despite profound therapeutic efficacy in pre-clinical models. The development of these promising immunotherapeutic agonists has been slowed by limited understanding of their underlying mechanisms of action and, in many cases, the resulting inability to separate off-target toxicity from on-target anti-tumor immunity. Recent discoveries illuminating the detailed immunobiology of existing agonist antibodies such as a-CD40 and a-4-1BB, coupled with new agonists targeting OX40 and CD27 into the clinic, has renewed optimism that these agents will show the therapeutic promise they have displayed in animal models. This symposium addressed how activation of stimulatory receptors on both T cells and antigen presenting cells can enhance tumor immunity both in animal models and in clinical trials. 

#PresentationSlides #Video #AnnualMeeting #HotTopic #SITC #TherapeuticAntibodies #Clinician #Industry #Oncologist #Researcher #2014

Statistics
0 Favorited
75 Views
8 Files
0 Shares
701 Downloads
Attachment(s)
pdf file
OX40 Presentation Slides   1.57 MB   1 version
Uploaded - 02-21-2017
Meeting: Hot Topic Symposium I: Accelerating Tumor Immunity with Agonist Antibodies; Presentation: T Cell Costimulation in Cancer Immunotherapy through Agonist Agents: OX40; Presenter: Andrew D. Weinberg, PhD – Earle A. Chiles Research Institute, Providence Portland Medical Center; Date: November 9, 2014
mp4 file
OX40 Presentation Video   83.97 MB   1 version
Uploaded - 03-28-2017
Meeting: Hot Topic Symposium I: Accelerating Tumor Immunity with Agonist Antibodies; Presentation: T Cell Costimulation in Cancer Immunotherapy through Agonist Agents: OX40; Presenter: Andrew D. Weinberg, PhD – Earle A. Chiles Research Institute, Providence Portland Medical Center; Date: November 9, 2014
pdf file
Enhancing Innate and Adaptive Immunity Presentation Slides   16.48 MB   1 version
Uploaded - 02-21-2017
Meeting: Hot Topic Symposium I: Accelerating Tumor Immunity with Agonist Antibodies; Presentation: 4-1BB: Enhancing Innate and Adaptive Immunity; Presenter: Holbrook E. Kohrt, MD, PhD – Stanford Cancer Institute; Date: November 9, 2014
mp4 file
Enhancing Innate and Adaptive Immunity Presentation Video   91.83 MB   1 version
Uploaded - 03-28-2017
Meeting: Hot Topic Symposium I: Accelerating Tumor Immunity with Agonist Antibodies; Presentation: 4-1BB: Enhancing Innate and Adaptive Immunity; Presenter: Holbrook E. Kohrt, MD, PhD – Stanford Cancer Institute; Date: November 9, 2014
pdf file
Anti-CD40 Agonist Antibody - The Ideal Combination Partne...   2.61 MB   1 version
Uploaded - 02-21-2017
Meeting: Hot Topic Symposium I: Accelerating Tumor Immunity with Agonist Antibodies; Presentation: Anti-CD40 Agonist Antibody - The Ideal Combination Partner for Cancer Immunotherapy; Presenter: Hy Levitsky, MD – Roche Glycart AG; Date: November 9, 2014
mp4 file
Anti-CD40 Agonist Antibody - The Ideal Combination Partne...   60.16 MB   1 version
Uploaded - 03-28-2017
Meeting: Hot Topic Symposium I: Accelerating Tumor Immunity with Agonist Antibodies; Presentation: Anti-CD40 Agonist Antibody - The Ideal Combination Partner for Cancer Immunotherapy; Presenter: Hy Levitsky, MD – Roche Glycart AG; Date: November 9, 2014
pdf file
A Novel Drug and Drug Delivery Platform for Cancer Immun...   1.19 MB   1 version
Uploaded - 02-21-2017
Meeting: Hot Topic Symposium I: Accelerating Tumor Immunity with Agonist Antibodies; Presentation: Oligonucleotide Aptamers: A Novel Drug and Drug Delivery Platform for Cancer Immunotherapy; Presenter: Eli Gilboa, PhD – University of Miami; Date: November 9, 2014
mp4 file
A Novel Drug and Drug Delivery Platform for Cancer Immun...   45.92 MB   1 version
Uploaded - 03-28-2017
Meeting: Hot Topic Symposium I: Accelerating Tumor Immunity with Agonist Antibodies; Presentation: Oligonucleotide Aptamers: A Novel Drug and Drug Delivery Platform for Cancer Immunotherapy; Presenter: Eli Gilboa, PhD – University of Miami; Date: November 9, 2014